Due to the infiltrative nature of glioblastoma (GBM) outside of the contrast-enhancing region on MRI, there is interest in exploring supratotal resections (SpTR) that extend beyond the contrast-enhancing portion of the tumor. However, there is currently no consensus on the potential survival benefit of SpTR in GBM compared to gross total resection (GTR). In this study, we compare the impact of SpTR versus GTR on overall survival (OS) of GBM patients.
We performed a systematic review and meta-analysis of literature published on PubMed, Embase, The Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov, from inception to August 16, 2018, to identify articles comparing OS after SpTR versus GTR.
We identified 8902 unique citations, of which 11 articles met study inclusion criteria. 810 patients underwent SpTR out of a total of 2056 patients. 9 of 11 studies demonstrated improved outcomes with SpTR compared to GTR (median improvement in OS of 10.5 months), with no significant difference in postoperative complication rate. Overall study quality was variable, with ten studies presenting level IV evidence and one study presenting level IIIb evidence. Subgroup meta-analysis based on SpTR definition demonstrated a statistically significant 35% lower risk of mortality in patients who underwent anatomical SpTR compared to patients who underwent GTR (Hazard ratio = 0.65, 95% CI 0.47- 0.91, p = 0.003).
Our systematic review indicates SpTR may be associated with improved OS compared to GTR for GBM, especially with anatomical SpTR. However, this is limited by variable study design and significant clinical and methodological heterogeneity among studies. There is need for prospective clinical data to further guide parameters regarding the use of SpTR in GBM.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA—J Am Med Assoc 310:1842–1850
Brada M, Hoang-Xuan K, Rampling R et al (2014) Glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 61:e9–e16. https://doi.org/10.1007/s10517-015-2864-2
Sanai N, Berger MS (2008) Glioma extent of resection and methods. Neurosurgery 62:753–766. https://doi.org/10.1227/01.NEU.0000310769.20996.BD
Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190
Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis. JAMA Oncol 2:1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373
Sanai N, Polley M-Y, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.JNS10998
Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988. https://doi.org/10.3171/2015.5.JNS142087
Dandy WE (1928) Removal of right cerebral hemisphere for certain tumors with hemiplegia: preliminary report. J Am Med Assoc 90:823–825. https://doi.org/10.1001/jama.1928.02690380007003
Baldock AL, Ahn S, Rockne R et al (2014) Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS ONE 9:e99057. https://doi.org/10.1371/journal.pone.0099057
Darmanis S, Sloan SA, Croote D et al (2017) Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 21:1399–1410. https://doi.org/10.1016/j.celrep.2017.10.030
Eyüpoglu IY, Buchfelder M, Savaskan NE (2013) Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol 9:141–151
Eidel O, Burth S, Neumann JO et al (2017) Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS ONE. https://doi.org/10.1371/journal.pone.0169292
Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas treatment. J Clin Oncol 21:1624–1636. https://doi.org/10.1200/JC0.2003.05.063
Rahman M, Abbatematteo J, De Leo EK et al (2017) The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 127:123–131. https://doi.org/10.3171/2016.7.JNS16396
McGirt MJ, Mukherjee D, Chaichana KL et al (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:463–469. https://doi.org/10.1227/01.NEU.0000349763.42238.E9
De Leeuw CN, Vogelbaum MA (2019) Supratotal resection in glioma: a systematic review. Neuro Oncol 21:179–188. https://doi.org/10.1093/neuonc/noy166
Incekara F, Koene S, Vincent AJPE et al (2019) Association between supratotal glioblastoma resection and patient survival: a systematic review and meta-analysis. World Neurosurg 127:617–624.e2
Liberati A, Altman DG, Tetzlaff J, et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097
Covidence—Better systematic review management
OCEBM Levels of Evidence—CEBM. https://www.cebm.net/index.aspx?o=5653
Guyot P, Ades AE, Ouwens MJNM, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. https://doi.org/10.1186/1471-2288-12-9
Liu Z, Rich B, Hanley JA (2015) Recovering the raw data behind a non-parametric survival curve. Syst Rev. https://doi.org/10.1186/2046-4053-3-151
Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186
Glenn CA, Baker CM, Conner AK et al (2018) An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg 114:e747–e755. https://doi.org/10.1016/j.wneu.2018.03.072
Esquenazi Y, Friedman E, Liu Z et al (2017) The Survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery 81:275–288. https://doi.org/10.1093/neuros/nyw174
Grabowski MM, Recinos PF, Nowacki AS et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115–1123. https://doi.org/10.3171/2014.7.JNS132449
Mampre D, Ehresman J, Pinilla-Monsalve G et al (2018) Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes. Br J Neurosurg 32:528–535. https://doi.org/10.1080/02688697.2018.1498450
De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115:37–43. https://doi.org/10.1016/j.clineuro.2012.04.005
Pessina F, Navarria P, Cozzi L et al (2017) Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 135:129–139. https://doi.org/10.1007/s11060-017-2559-9
Hamada S, Abou-Zeid A (2016) Anatomical resection in glioblastoma: extent of resection and its impact on duration of survival. Egypt J Neurol Psychiatry Neurosurg. https://doi.org/10.4103/1110-1083.192655
Eypoglu IY, Hore N, Merkel A et al (2016) Supra-complete surgery via dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. Oncotarget 7:25755–25768
Aldave G, Tejada S, Pay E et al (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 72:915–920. https://doi.org/10.1227/NEU.0b013e31828c3974
Grossman R, Shimony N, Shir D et al (2017) Dynamics of FLAIR volume changes in glioblastoma and prediction of survival. Ann Surg Oncol 24:794–800. https://doi.org/10.1245/s10434-016-5635-z
Binabaj MM, Bahrami A, ShahidSales S et al (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233:378–386. https://doi.org/10.1002/jcp.25896
Chen JR, Yao Y, Xu HZ, Qin ZY (2016) Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Med (United States) 95:e2583. https://doi.org/10.1097/MD.0000000000002583
Yang P, Zhang W, Wang Y et al (2015) IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget 6:40896–40906
Zou P, Xu H, Chen P et al (2013) IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS ONE 8:e68782. https://doi.org/10.1371/journal.pone.0068782
Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91. https://doi.org/10.1093/neuonc/not159
Chaichana K, Zadnik P, Weingart J et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–920. https://doi.org/10.3171/2012.0.JNS1277
Perrini P, Gambacciani C, Weiss A et al (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol 131(3):585–591. https://doi.org/10.1007/s11060-016-2330-7
M.L. obtains research support from Aegenus, Accuray, Bristol-Myer Squibb and DNAtrix.
Conflict of interest
C.B. is a consultant for Depuy-Synthes and M.L. is a consult for Tocagen, SQ Technologies, Stryker, and Baxter.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jackson, C., Choi, J., Khalafallah, A.M. et al. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol 148, 419–431 (2020). https://doi.org/10.1007/s11060-020-03556-y
- Extent of resection
- Supratotal resection
- T2 FLAIR